Chengdu Wentai Pharmaceutical Technology

Chengdu Wentai Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative small molecule drugs for metabolic and cardiovascular diseases. The company's research focuses on high-potential targets such as GPR119 and SGLT2 to address the growing global burden of type 2 diabetes and obesity. Its lead asset, WT-2106, is a novel GPR119 agonist designed to improve glucose-dependent insulin secretion and preserve beta-cell function. Chengdu Wentai integrates advanced medicinal chemistry and pharmacological screening to advance its pipeline from discovery through clinical proof-of-concept.